309 related articles for article (PubMed ID: 26857285)
21. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.
Baron F; Zachée P; Maertens J; Kerre T; Ory A; Seidel L; Graux C; Lewalle P; Van Gelder M; Theunissen K; Willems E; Emonds MP; De Becker A; Beguin Y
J Hematol Oncol; 2015 Feb; 8():4. PubMed ID: 25652604
[TBL] [Abstract][Full Text] [Related]
22. Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin.
Yu ZP; Ding JH; Wu F; Liu J; Wang J; Cheng J; Zhao G
Biol Blood Marrow Transplant; 2012 Apr; 18(4):593-9. PubMed ID: 21846461
[TBL] [Abstract][Full Text] [Related]
23. Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies.
Li Q; Meng F; Zhou M; Yu B; Mo W; Du Q; Jiang X; Wei Y
Med Sci Monit; 2015 Aug; 21():2257-65. PubMed ID: 26238068
[TBL] [Abstract][Full Text] [Related]
24. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience.
Zhou L; Gao ZY; Lu DP
Ann Hematol; 2020 Jun; 99(6):1389-1400. PubMed ID: 32291495
[TBL] [Abstract][Full Text] [Related]
25. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
26. HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG: thymoglobulin).
Kako S; Akahoshi Y; Harada N; Nakano H; Kameda K; Ugai T; Yamasaki R; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kanda Y
Hematology; 2017 Apr; 22(3):129-135. PubMed ID: 27905258
[TBL] [Abstract][Full Text] [Related]
27. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis.
Admiraal R; Nierkens S; de Witte MA; Petersen EJ; Fleurke GJ; Verrest L; Belitser SV; Bredius RGM; Raymakers RAP; Knibbe CAJ; Minnema MC; van Kesteren C; Kuball J; Boelens JJ
Lancet Haematol; 2017 Apr; 4(4):e183-e191. PubMed ID: 28330607
[TBL] [Abstract][Full Text] [Related]
28. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
29. Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation.
Kawamura K; Kanda J; Fuji S; Murata M; Ikegame K; Yoshioka K; Fukuda T; Ozawa Y; Uchida N; Iwato K; Sakura T; Hidaka M; Hashimoto H; Ichinohe T; Atsuta Y; Kanda Y
Bone Marrow Transplant; 2017 Oct; 52(10):1390-1398. PubMed ID: 28714944
[TBL] [Abstract][Full Text] [Related]
30. Hematopoietic Stem Cell Transplantation From a Related Donor with Human Leukocyte Antigen 1-Antigen Mismatch in the Graft-Versus-Host Direction Using Low-dose Anti-thymocyte Globulin.
Kanda J; Ando T; Kimura SI; Fujiwara SI; Imada K; Fujisawa S; Tachibana T; Atsuta Y; Kanda Y
Cell Transplant; 2020; 29():963689720976567. PubMed ID: 33267617
[TBL] [Abstract][Full Text] [Related]
31. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.
Cho BS; Min GJ; Park SS; Yoon SY; Park S; Jeon YW; Shin SH; Yahng SA; Yoon JH; Lee SE; Eom KS; Kim YJ; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ; Lee S
Am J Hematol; 2021 Nov; 96(11):1441-1449. PubMed ID: 34390504
[TBL] [Abstract][Full Text] [Related]
32. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation.
Pidala J; Tomblyn M; Nishihori T; Ayala E; Field T; Fernandez H; Perez L; Locke F; Alsina M; Ochoa JL; Perkins J; Tate C; Shapiro J; Conwell M; Bookout R; Anasetti C
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1237-44. PubMed ID: 21215811
[TBL] [Abstract][Full Text] [Related]
33. In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation.
Nachbaur D; Eibl B; Kropshofer G; Meister B; Mitterschiffthaler A; Schennach H; Fischer G; Kopp M; Gunsilius E; Gastl G
J Hematother Stem Cell Res; 2002 Aug; 11(4):731-7. PubMed ID: 12201962
[TBL] [Abstract][Full Text] [Related]
34. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis.
Admiraal R; van Kesteren C; Jol-van der Zijde CM; Lankester AC; Bierings MB; Egberts TC; van Tol MJ; Knibbe CA; Bredius RG; Boelens JJ
Lancet Haematol; 2015 May; 2(5):e194-203. PubMed ID: 26688094
[TBL] [Abstract][Full Text] [Related]
35. Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation?
Heelan F; Mallick R; Bryant A; Radhwi O; Atkins H; Huebsch L; Bredeson C; Allan D; Kekre N
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1298-1302. PubMed ID: 32165325
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of patients with hematological malignancies who undergo unrelated donor hematopoietic stem cell transplantation with ATG-Fresenius versus ATG-Genzyme.
Wang L; Kong P; Zhang C; Gao L; Zhu L; Liu J; Gao S; Chen T; Liu H; Yao H; Liu Y; Feng Y; Zhao L; Li Y; Gao L; Zhang X
Ann Hematol; 2023 Jun; 102(6):1569-1579. PubMed ID: 37097455
[TBL] [Abstract][Full Text] [Related]
37. Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin.
Hatanaka K; Fuji S; Ikegame K; Kato R; Wake A; Hidaka M; Ito T; Inoue M; Nagatoshi Y; Takami A; Uike N; Sakamaki H; Yabe H; Morishima Y; Suzuki R; Atsuta Y; Fukuda T
Int J Hematol; 2012 Dec; 96(6):773-80. PubMed ID: 23132596
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.
Yuan J; Pei R; Su W; Cao J; Lu Y
Oncotarget; 2017 Feb; 8(7):10871-10882. PubMed ID: 28107198
[TBL] [Abstract][Full Text] [Related]
39. Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation.
Binkert L; Medinger M; Halter JP; Heim D; Gerull S; Holbro A; Lengerke C; Weisser M; Passweg JR
Bone Marrow Transplant; 2015 Oct; 50(10):1331-6. PubMed ID: 26121111
[TBL] [Abstract][Full Text] [Related]
40. A comparison of post-transplantation cyclophosphamide versus antithymocyte-globulin in patients with hematological malignancies undergoing HLA-matched unrelated donor transplantation.
Lee MW; Yeon SH; Seo WH; Ryu H; Lee HJ; Yun HJ; Jo DY; Song IC
Medicine (Baltimore); 2020 Aug; 99(34):e21571. PubMed ID: 32846764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]